Bayer’s Kerendia Kidney Data And FDA Review Shift Long Term Outlook
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
Bayer’s KERENDIA Priority Review Highlights Cardiorenal Opportunity And Pipeline Execution Risk
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
KEY FACTS: Regulatory submission is based on positive results from the Phase III OCEANIC-STROKE study OCEANIC-STROKE met the…
Should FDA Priority Review for HYRNUO’s First-Line Lung Cancer Use Require Action From Bayer (XTRA:BAYN) Investors?
Bayer recently announced that the U.S. FDA has granted Priority Review to HYRNUO (sevabertinib) as a first-line treatment…